One Analyst's Top 5 Takeaways from Johnson & Johnson's Analyst Day

Johnson & Johnson JNJ hosted its annual analyst day earlier this week. Credit Suisse didn't see anything materially changing their view of the company's stock, but still had some notable takeaways.

• "Strong commitment to broad footprint."
• "Technology, innovation and business development overarching themes of the day."
• "Consumer topline performance improving, with margin expansion likely to follow."
• "JNJ also expecting accelerating market growth in Medical Devices."
• "Attention now shifts back to Pharma at ASCO."

Credit Suisse holds a Neutral rating and $112 price target on shares. The stock closed Thursday at $112.85, down 0.6 percent.